Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy.
暂无分享，去创建一个
E. Bertini | A. D’Amico | S. Cascioli | M. Vivarelli | F. De Benedetti | M. Colucci | M. Catteruccia
[1] A. Schenone,et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[2] J. Pollard,et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision , 2010, European journal of neurology.
[3] M. Gobbi,et al. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura , 2008, Muscle & nerve.
[4] E. Haddad,et al. Evolution and treatment of childhood chronic inflammatory polyneuropathy. , 2007, Pediatric neurology.
[5] C. Briani,et al. Rituximab‐responsive CIDP , 2004, European journal of neurology.